

Fabiola Traina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9220203/publications.pdf>

Version: 2024-02-01

148
papers

3,288
citations

172207

29
h-index

182168

51
g-index

151
all docs

151
docs citations

151
times ranked

5149
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. <i>Blood</i> , 2011, 118, 3932-3941.	0.6	290
2	Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. <i>Leukemia</i> , 2014, 28, 78-87.	3.3	256
3	SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. <i>Leukemia</i> , 2012, 26, 542-545.	3.3	203
4	SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. <i>Blood</i> , 2012, 120, 3173-3186.	0.6	173
5	Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis. <i>PLoS ONE</i> , 2012, 7, e43090.	1.1	97
6	Rho Kinase Regulates the Survival and Transformation of Cells Bearing Oncogenic Forms of KIT, FLT3, and BCR-ABL. <i>Cancer Cell</i> , 2011, 20, 357-369.	7.7	84
7	Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. <i>Haematologica</i> , 2013, 98, 107-113.	1.7	68
8	Loss of long noncoding RNA FOXF1-AS1 regulates epithelial-mesenchymal transition, stemness and metastasis of non-small cell lung cancer cells. <i>Oncotarget</i> , 2016, 7, 68339-68349.	0.8	64
9	ARHGAP21 is a RhoGAP for RhoA and RhoC with a role in proliferation and migration of prostate adenocarcinoma cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 365-374.	1.8	50
10	CXCR7 Is Highly Expressed in Acute Lymphoblastic Leukemia and Potentiates CXCR4 Response to CXCL12. <i>PLoS ONE</i> , 2014, 9, e85926.	1.1	49
11	Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis. <i>Blood</i> , 2020, 135, 870-875.	0.6	48
12	Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. <i>Leukemia Research</i> , 2014, 38, 1245-1251.	0.4	47
13	Human leukocyte formin: a novel protein expressed in lymphoid malignancies and associated with Akt. <i>Biochemical and Biophysical Research Communications</i> , 2003, 311, 365-371.	1.0	46
14	ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells. <i>Experimental Cell Research</i> , 2014, 324, 137-145.	1.2	46
15	Expansion strategies for human mesenchymal stromal cells culture under xeno-free conditions. <i>Biotechnology Progress</i> , 2017, 33, 1358-1367.	1.3	46
16	Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties. <i>European Journal of Haematology</i> , 2006, 78, 061205033335001-???	1.1	42
17	Updates in Cytogenetics and Molecular Markers in MDS. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 126-135.	1.2	42
18	Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning. <i>Bone Marrow Transplantation</i> , 2005, 35, 277-282.	1.3	41

#	ARTICLE	IF	CITATIONS
19	FMNL1 promotes proliferation and migration of leukemia cells. <i>Journal of Leukocyte Biology</i> , 2013, 94, 503-512.	1.5	41
20	Hydroxyurea is associated with reductions in hypercoagulability markers in sickle cell anemia. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1967-1970.	1.9	39
21	Stathmin 1 in normal and malignant hematopoiesis. <i>BMB Reports</i> , 2014, 47, 660-665.	1.1	36
22	Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis. <i>Clinics</i> , 2018, 73, e566s.	0.6	35
23	Endothelial Activation by Platelets from Sickle Cell Anemia Patients. <i>PLoS ONE</i> , 2014, 9, e89012.	1.1	35
24	Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea. <i>Haematologica</i> , 2015, 100, 730-739.	1.7	34
25	ANKHD1, ankyrin repeat and KH domain containing 1, is overexpressed in acute leukemias and is associated with SHP2 in K562 cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2006, 1762, 828-834.	1.8	33
26	Role for cAMP-protein kinase A signalling in augmented neutrophil adhesion and chemotaxis in sickle cell disease. <i>European Journal of Haematology</i> , 2007, 79, 330-337.	1.1	33
27	Low bone mass density is associated with hemolysis in brazilian patients with sickle cell disease. <i>Clinics</i> , 2011, 66, 801-805.	0.6	33
28	Participation of Mac-1, LFA-1 and VLA-4 integrins in the in vitro adhesion of sickle cell disease neutrophils to endothelial layers, and reversal of adhesion by simvastatin. <i>Haematologica</i> , 2011, 96, 526-533.	1.7	33
29	IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells. <i>Cancer Letters</i> , 2019, 456, 59-68.	3.2	31
30	High expression of FMNL1 protein in T non-Hodgkin's lymphomas. <i>Leukemia Research</i> , 2006, 30, 735-738.	0.4	30
31	High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils. <i>British Journal of Haematology</i> , 2008, 142, 836-844.	1.2	30
32	Elevated plasma levels and platelet-associated expression of the pro-thrombotic and pro-inflammatory protein, <i>scpt</i> /NFSF14 (LIGHT), in sickle cell disease. <i>British Journal of Haematology</i> , 2012, 158, 788-797.	1.2	30
33	Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation. <i>Hematology, Transfusion and Cell Therapy</i> , 2018, 40, 120-131.	0.1	30
34	Chronic Liver Abnormalities in Sickle Cell Disease: A Clinicopathological Study in 70 Living Patients. <i>Acta Haematologica</i> , 2007, 118, 129-135.	0.7	29
35	Elevated hypercoagulability markers in hemoglobin SC disease. <i>Haematologica</i> , 2015, 100, 466-471.	1.7	29
36	De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes. <i>Scientific Reports</i> , 2017, 7, 40707.	1.6	29

#	ARTICLE	IF	CITATIONS
37	Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells. <i>Leukemia Research</i> , 2014, 38, 251-257.	0.4	28
38	BCR-ABL binds to IRS-1 and IRS-1 phosphorylation is inhibited by imatinib in K562 cells. <i>FEBS Letters</i> , 2003, 535, 17-22.	1.3	27
39	NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 5.	7.1	26
40	Inhibition of caspase-dependent spontaneous apoptosis via a cAMP-protein kinase A dependent pathway in neutrophils from sickle cell disease patients. <i>British Journal of Haematology</i> , 2007, 139, 148-158.	1.2	25
41	Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 450-461.	1.8	25
42	Increased adhesive properties of platelets in sickle cell disease: roles for α IIb β 3-mediated ligand binding, diminished cAMP signalling and increased phosphodiesterase 3A activity. <i>British Journal of Haematology</i> , 2010, 149, 280-288.	1.2	24
43	The Prognostic Relevance of Apoptosis-related Proteins in Classical Hodgkin's Lymphomas. <i>Leukemia and Lymphoma</i> , 2003, 44, 483-488.	0.6	23
44	IL10 inversely correlates with the percentage of CD8+ cells in MDS patients. <i>Leukemia Research</i> , 2013, 37, 541-546.	0.4	23
45	ANKHD1 silencing inhibits Stathmin 1 activity, cell proliferation and migration of leukemia cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 583-593.	1.9	23
46	Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2011, 1813, 1404-1411.	1.9	22
47	Immunophenotyping in Myelodysplastic Syndromes Can Add Prognostic Information to Well-Established and New Clinical Scores. <i>PLoS ONE</i> , 2013, 8, e81048.	1.1	22
48	Molecular matching for Rh and K reduces red blood cell alloimmunisation in patients with myelodysplastic syndrome. <i>Blood Transfusion</i> , 2015, 13, 53-8.	0.3	22
49	Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. <i>Journal of Hematology and Oncology</i> , 2012, 5, 4.	6.9	21
50	Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia. <i>European Journal of Cancer</i> , 2015, 51, 2076-2085.	1.3	21
51	PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia. <i>Cancer Genetics</i> , 2019, 233-234, 56-66.	0.2	21
52	Characterization of Human AB Serum for Mesenchymal Stromal Cell Expansion. <i>Transfusion Medicine and Hemotherapy</i> , 2017, 44, 11-21.	0.7	20
53	CATS (FAM64A) abnormal expression reduces clonogenicity of hematopoietic cells. <i>Oncotarget</i> , 2016, 7, 68385-68396.	0.8	20
54	IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. <i>Oncotarget</i> , 2016, 7, 6948-6959.	0.8	20

#	ARTICLE	IF	CITATIONS
55	Inhibition of phosphodiesterase 9A reduces cytokine-stimulated in vitro adhesion of neutrophils from sickle cell anemia individuals. <i>Inflammation Research</i> , 2011, 60, 633-642.	1.6	19
56	Altered red cell and platelet adhesion in hemolytic diseases: Hereditary spherocytosis, paroxysmal nocturnal hemoglobinuria and sickle cell disease. <i>Clinical Biochemistry</i> , 2013, 46, 1798-1803.	0.8	19
57	Single-nucleotide polymorphism array (SNP-A) improves the identification of chromosomal abnormalities by metaphase cytogenetics in myelodysplastic syndrome. <i>Journal of Clinical Pathology</i> , 2017, 70, 435-442.	1.0	19
58	Tissue factor-dependent coagulation activation by heme: A thromboelastometry study. <i>PLoS ONE</i> , 2017, 12, e0176505.	1.1	19
59	Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens. <i>Bone Marrow Transplantation</i> , 2008, 41, 887-893.	1.3	18
60	Distinct expression profiles of MSI2 and NUMB genes in myelodysplastic syndromes and acute myeloid leukemia patients. <i>Leukemia Research</i> , 2012, 36, 1300-1303.	0.4	18
61	Ten-eleven-translocation 2 (<i>TET2</i>) is downregulated in myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2015, 94, 413-418.	1.1	18
62	IRS1/ β -Catenin Axis Is Activated and Induces MYC Expression in Acute Lymphoblastic Leukemia Cells. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 1774-1781.	1.2	17
63	Low Ten-eleven-translocation 2 (<i>TET2</i>) transcript level is independent of <i>TET2</i> mutation in patients with myeloid neoplasms. <i>Diagnostic Pathology</i> , 2016, 11, 28.	0.9	16
64	Telomere dynamics and hematopoietic differentiation of human <i>DKC1</i> -mutant induced pluripotent stem cells. <i>Stem Cell Research</i> , 2019, 40, 101540.	0.3	16
65	Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 1105-1117.	2.1	16
66	Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in <i>JAK2V617F</i> cells. <i>Oncotarget</i> , 2015, 6, 29573-29584.	0.8	16
67	Conventional chemotherapy for acute myeloid leukemia: a Brazilian experience. <i>Sao Paulo Medical Journal</i> , 2000, 118, 173-178.	0.4	15
68	BNIP3L in myelodysplastic syndromes and acute myeloid leukemia: impact on disease outcome and cellular response to decitabine. <i>Haematologica</i> , 2016, 101, e445-e448.	1.7	15
69	Identification of protein-coding and non-coding RNA expression profiles in CD34+ and in stromal cells in refractory anemia with ringed sideroblasts. <i>BMC Medical Genomics</i> , 2010, 3, 30.	0.7	14
70	Downregulation of <i>IRS2</i> in myelodysplastic syndrome: A possible role in impaired hematopoietic cell differentiation. <i>Leukemia Research</i> , 2012, 36, 931-935.	0.4	14
71	Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors. <i>Diagnostic Pathology</i> , 2015, 10, 44.	0.9	14
72	Imatinib restores VASP activity and its interaction with Zyxin in BCR-ABL leukemic cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 388-395.	1.9	14

#	ARTICLE	IF	CITATIONS
73	Reversine triggers mitotic catastrophe and apoptosis in K562 cells. <i>Leukemia Research</i> , 2016, 48, 26-31.	0.4	14
74	Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms. <i>Cell Death and Disease</i> , 2018, 9, 311.	2.7	14
75	Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells. <i>Investigational New Drugs</i> , 2020, 38, 733-745.	1.2	13
76	SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype. <i>Haematologica</i> , 2013, 98, e105-e107.	1.7	12
77	Reversine exhibits antineoplastic activity in JAK2V617F-positive myeloproliferative neoplasms. <i>Scientific Reports</i> , 2019, 9, 9895.	1.6	12
78	<i>YAP1</i> expression in myelodysplastic syndromes and acute leukemias. <i>Leukemia and Lymphoma</i> , 2014, 55, 2413-2415.	0.6	11
79	Abnormal Hedgehog pathway in myelodysplastic syndrome and its impact on patients' outcome. <i>Haematologica</i> , 2015, 100, e491-e493.	1.7	11
80	Assessment of liver and cardiac iron overload using MRI in patients with chronic anemias in Latin American countries: results from ASIMILA study. <i>Hematology</i> , 2018, 23, 676-682.	0.7	11
81	Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 2339-2350.	2.5	11
82	Post-translational modification of the RhoGTPase activating protein 21, ARHGAP21, by SUMO2/3. <i>FEBS Letters</i> , 2012, 586, 3522-3528.	1.3	10
83	Effects of thalidomide on long-term bone marrow cultures from patients with myelodysplastic syndromes: Induction of IL-10 expression in the stromal layers. <i>Leukemia Research</i> , 2011, 35, 1102-1107.	0.4	9
84	Paclitaxel induces Stathmin 1 phosphorylation, microtubule stability and apoptosis in acute lymphoblastic leukemia cells. <i>Heliyon</i> , 2017, 3, e00405.	1.4	9
85	MDR-1 and GST polymorphisms are involved in myelodysplasia progression. <i>Leukemia Research</i> , 2013, 37, 970-973.	0.4	8
86	Serine Protease Inhibitor Kunitz-Type 2 Is Downregulated in Myelodysplastic Syndromes and Modulates Cell-Cell Adhesion. <i>Stem Cells and Development</i> , 2014, 23, 1109-1120.	1.1	8
87	The U2AF homology motif kinase 1 (UHMK1) is upregulated upon hematopoietic cell differentiation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 959-966.	1.8	8
88	VARIATION OF BONE MARROW CD34+ CELL SUBSETS IN MYELODYSPLASTIC SYNDROMES ACCORDING TO WHO TYPES. <i>Neoplasma</i> , 2009, 56, 435-440.	0.7	8
89	Identification of target genes using gene expression profile of granulocytes from patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2014, 55, 1861-1869.	0.6	7
90	NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. <i>Investigational New Drugs</i> , 2021, 39, 736-746.	1.2	7

#	ARTICLE	IF	CITATIONS
91	The impact of several phenotypic features at diagnosis on survival of patients with myelodysplastic syndromes. <i>Neoplasma</i> , 2010, 57, 530-536.	0.7	7
92	Differential profile of PIP4K2A expression in hematological malignancies. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 55, 228-235.	0.6	6
93	Clinical features of JAK2V617F- or CALR-mutated essential thrombocythemia and primary myelofibrosis. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 60, 74-77.	0.6	6
94	Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 1191-1201.	2.1	6
95	A multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings?. <i>Leukemia and Lymphoma</i> , 2021, 62, 147-157.	0.6	6
96	STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. <i>Investigational New Drugs</i> , 2022, 40, 438-452.	1.2	6
97	Increased expression of <i>APAF1</i> in low-risk myelodysplastic syndrome: a possible role in the pathophysiology of myelodysplasia. <i>European Journal of Haematology</i> , 2010, 84, 525-530.	1.1	5
98	Co-occurrence of BCR-ABL1-positive chronic myeloid leukaemia and CALR-mutated essential thrombocythaemia. <i>British Journal of Haematology</i> , 2020, 188, e21-e23.	1.2	5
99	NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia. <i>Scientific Reports</i> , 2020, 10, 10315.	1.6	5
100	MLL5 improves ATRA driven differentiation and promotes xenotransplant engraftment in acute promyelocytic leukemia model. <i>Cell Death and Disease</i> , 2021, 12, 371.	2.7	5
101	Reduced expression of FLIPSHORT in bone marrow of low risk myelodysplastic syndrome. <i>Leukemia Research</i> , 2007, 31, 853-857.	0.4	4
102	Deficiência de ferro no paciente submetido à ressecção gástrica ou intestinal: prevalência, causas, repercussões clínicas, abordagem diagnóstica e prevenção. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2010, 32, 78-83.	0.7	4
103	Lack of association between MDM2 SNP309 and TP53 Arg72Pro polymorphisms with clinical outcomes in myelodysplastic syndrome. <i>Neoplasma</i> , 2012, 59, 530-535.	0.7	4
104	Effects of RhoA and RhoC upon the sensitivity of prostate cancer cells to glutamine deprivation. <i>Small GTPases</i> , 2021, 12, 20-26.	0.7	4
105	Characterisation of a new splice variant of MASK-BP3ARF and MASK human genes, and their expression patterns during haematopoietic cell differentiation. <i>Gene</i> , 2005, 363, 113-122.	1.0	3
106	A case of mistaken identity: When lupus masquerades as primary myelofibrosis. <i>SAGE Open Medical Case Reports</i> , 2013, 1, 2050313X1349870.	0.2	3
107	Compound Heterozygous RAG2 Mutations Mimicking Hyper IgM Syndrome. <i>Journal of Clinical Immunology</i> , 2014, 34, 7-9.	2.0	3
108	Pyrimidine-5-nucleotidase Campinas, a new mutation (p.R56G) in the NT5C3 gene associated with pyrimidine-5-nucleotidase type I deficiency and influence of Gilbert's Syndrome on clinical expression. <i>Blood Cells, Molecules, and Diseases</i> , 2014, 53, 246-252.	0.6	3

#	ARTICLE	IF	CITATIONS
109	Fetal hemoglobin and hemolysis markers in sickle cell anemia. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2015, 37, 148-149.	0.7	3
110	New germline GATA1 variant in females with anemia and thrombocytopenia. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 88, 102545.	0.6	3
111	Metaphase cytogenetics and single nucleotide polymorphism arrays in myeloid malignancies. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2015, 37, 71-72.	0.7	2
112	Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2015, 37, 211-214.	0.7	2
113	Reactive oxygen species overload promotes apoptosis in JAK2V617F-positive cell lines. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016, 38, 179-181.	0.7	2
114	Differential profile of CDKN1A and TP53 expressions in bone marrow mesenchymal stromal cells from myeloid neoplasms. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016, 38, 368-370.	0.7	2
115	Acquired Angioedema due to C1 Inhibitor Deficiency Preceding Splenic Marginal Zone Lymphoma: Further Insights from Clinical Practice. <i>International Archives of Allergy and Immunology</i> , 2020, 181, 941-946.	0.9	2
116	Molecular-Based Score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome. <i>Scientific Reports</i> , 2021, 11, 1675.	1.6	2
117	Low expression of tissue inhibitor of metalloproteinase-2 may be associated with high-risk myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2013, 54, 1091-1093.	0.6	1
118	Myelodysplastic syndrome with synchronous gastric cancer: when the symptoms suggest something else. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2014, 36, 442-444.	0.7	1
119	Stathmin 1 expression in plasma cell neoplasms. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2017, 39, 183-185.	0.7	1
120	Acute myeloid leukemia with e1a2 BCR-ABL1 fusion gene: two cases with peculiar molecular and clinical presentations. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2017, 39, 379-384.	0.7	1
121	IRS2 (insulin receptor substrate 2). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2018, , .	0.1	1
122	Metformin Suppress Cellular and Molecular Processes Related to Maintenance and Proliferation of Myeloproliferative Neoplasm Stem Cell. <i>Blood</i> , 2019, 134, 1682-1682.	0.6	1
123	Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells. <i>Toxicology in Vitro</i> , 2022, 83, 105384.	1.1	1
124	Indicações de transplante de células-tronco hematopoéticas para pacientes com diagnóstico de síndromes mielodisplásicas. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2006, 28, 221.	0.7	0
125	P079 Increase in bone marrow immature nonlymphoid early precursors are indicative of a short survival in myelodysplastic syndromes. <i>Leukemia Research</i> , 2009, 33, S104.	0.4	0
126	Clofarabine for myelodysplastic syndromes. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1005-1014.	1.9	0

#	ARTICLE	IF	CITATIONS
127	SIVA, a target of p53, is downregulated in myelodysplastic syndromes. <i>Applied Cancer Research</i> , 2017, 37, .	1.0	0
128	The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study. <i>Blood Advances</i> , 2017, 1, 86-89.	2.5	0
129	Feasibility of minimal residual disease studies by multiparametric flow cytometry for acute myeloid leukemia in a developing country. <i>Blood Advances</i> , 2017, 1, 80-83.	2.5	0
130	TET2 is upregulated during erythroid differentiation of CD34+ cells from healthy donors and myelodysplastic syndrome patients. <i>Applied Cancer Research</i> , 2017, 37, .	1.0	0
131	IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes. <i>Hematology, Transfusion and Cell Therapy</i> , 2018, 40, 92-95.	0.1	0
132	High Expression of Human Leukocyte Formin Protein in T Non-Hodgkinâ€™s Lymphomas and in CD19â€™ Cell Population of Normal Tonsils.. <i>Blood</i> , 2005, 106, 4662-4662.	0.6	0
133	Altered Red Cell and Platelet Adhesion in the Hemolytic Diseases: Hereditary Spherocytosis, Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Anemia.. <i>Blood</i> , 2006, 108, 1238-1238.	0.6	0
134	ANKHD1, a New Ankyrin-Repeat Protein, Binds to SIVA and May Modulate ROS Generation, Cell Cycle and Apoptosis Signaling in Cancer Cells. <i>Blood</i> , 2008, 112, 5319-5319.	0.6	0
135	Inhibition of Phosphodiesterase 9A (PDE9A) Significantly Reduces Cytokine-Stimulated Adhesion of Neutrophils From Sickle Cell Disease Individuals, in Vitro, but Not Red Cell Adhesion.. <i>Blood</i> , 2009, 114, 1520-1520.	0.6	0
136	Hydroxyurea Therapy Is Associated with Decreased Platelet Aggregation Responses and Activation in Sickle Cell Disease.. <i>Blood</i> , 2009, 114, 2565-2565.	0.6	0
137	New TET2, ASXL1 and CBL Mutations Have Poor Prognostic Impact In Systemic Mastocytosis and Related Disorders. <i>Blood</i> , 2010, 116, 3076-3076.	0.6	0
138	Formin-Like 1 (FMNL1) Associates with Rac1 and Negatively Regulates Neoplastic Growth and Migration in Leukemia Cell Lines.. <i>Blood</i> , 2010, 116, 1030-1030.	0.6	0
139	IRS2 Is Dowregulated In Primary MDS Cells and During MDS Erythroid Differentiation. <i>Blood</i> , 2010, 116, 1886-1886.	0.6	0
140	Knockdown of Insulin Receptor Substrate 1 (IRS1); a Partner of BCR-ABL, Results In Decrease In Proliferation and Downregulation of AKT/mTOR and MAPK Pathways In K562 Cells. <i>Blood</i> , 2010, 116, 4459-4459.	0.6	0
141	Platelets From Sickle Cell Disease Individuals Induce Endothelial Activation, Demonstrating ICAM-1 and E-Selectin Adhesion Molecule Expression, Inflammatory Cytokine Production and Activation of NFÎ²B Transcription Factor Gene Expression.. <i>Blood</i> , 2012, 120, 2114-2114.	0.6	0
142	ANKHD1 Interacts with the Proapoptotic Protein SIVA and Plays a Role in the Proliferation and Stathmin Activation of Acute Leukemia Cells.. <i>Blood</i> , 2012, 120, 2419-2419.	0.6	0
143	PTK2 and PTPN11 expression in myelodysplastic syndromes. <i>Clinics</i> , 2013, 68, 1371-1375.	0.6	0
144	Hypercoagulability and Sickle Cell Disease. , 2016, , 109-127.		0

#	ARTICLE	IF	CITATIONS
145	Pharmacological IRS1/2 Inhibition Induces Apoptosis in BCR-ABL1T315I mutant Cells. Blood, 2016, 128, 1886-1886.	0.6	0
146	Nuclear SET Domain (NSD) Protein Lysine Methyltransferases (KMT) Family Members Expression in Acute Myeloid Leukemia. Blood, 2016, 128, 5097-5097.	0.6	0
147	Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model. Investigational New Drugs, 2022, , 1.	1.2	0
148	Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel. Hematology, Transfusion and Cell Therapy, 2022, , .	0.1	0